CCO Management Series
Evolving Standards of Care in Non-Hodgkin’s Lymphoma: A Clinical Management Series
Interactive Virtual Presentations
Diffuse Large B-Cell Lymphoma: Current Standards of Care and Clinical Advances
|
Program Director: James O. Armitage, MD
- Christopher R. Flowers, MD, MS
|
|
|
Christopher R. Flowers, MD, MS, provides an interactive case–based overview of standard and investigational treatment strategies for patients with diffuse large B-cell lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe current treatment approaches, including CHOP and R-CHOP, for the treatment of diffuse large B-cell lymphoma
- Identify diffuse large B-cell lymphoma patient subgroups who are more likely to benefit from immunochemotherapy
- Discuss the use of gene expression profiling to identify novel agents for diffuse large B-cell lymphoma
- Cite novel agents currently under investigation in clinical trials for the treatment of diffuse large B-cell lymphoma
|
Slideset: Diffuse Large B-Cell Lymphoma: Current Standards of Care and Clinical Advances
 |
|
Download slides focused on the standard and investigational treatment strategies for patients with diffuse large B-cell lymphoma.
Format: Microsoft PowerPoint (.ppt) |
File size: 3.84 MB
| Date posted: 6/11/2010
|
Mantle Cell Lymphoma: Is There a Potential for Cure?
|
Program Director: James O. Armitage, MD
- Andrew D. Zelenetz, MD, PhD
|
|
|
Andrew D. Zelenetz, MD, PhD, explores the current and emerging treatment options for patients with mantle cell lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain to patients how the proliferation index can be an important factor for predicting long-term outcomes in patients with mantle cell lymphoma
- Integrate targeted therapies into the treatment paradigm for patients with mantle cell lymphoma
- Recommend radioimmunotherapy as a management approach for patients with mantle cell lymphoma
- Appraise the role for aggressive consolidation treatment for patients with mantle cell lymphoma
|
Slideset: Mantle Cell Lymphoma: Is There a Potential for Cure?
 |
|
Download slides focused on the biology of mantle cell lymphoma, prognostic factors, and current and emerging treatment strategies.
Format: Microsoft PowerPoint (.ppt) |
File size: 4.39 MB
| Date posted: 7/14/2010
|
Relapsed/Refractory Mantle Cell Lymphoma: Is There a Potential for Cure?
- Andrew D. Zelenetz, MD, PhD
|
|
|
Andrew D. Zelenetz, MD, PhD, reviews the latest data on management strategies for patients with relapsed/refractory mantle cell lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Assess the optimal use of standard and emerging treatment options, both as single agents and combinations, for patients with relapsed/refractory mantle cell lymphoma
- Evaluate the role of autologous and allogeneic stem cell transplantation for the management of patients with relapsed/refractory mantle cell lymphoma
- Analyze recent data on the adverse events associated with use of combination regimens for patients with relapsed/refractory mantle cell lymphoma
|
Slideset: Relapsed/Refractory Mantle Cell Lymphoma: Is There a Potential for Cure?
 |
|
Download slides focused on standard and investigational treatment strategies for patients with mantle cell lymphoma in the relapsed setting.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.59 MB
| Date posted: 8/3/2010
|
The Evolving Treatment Paradigm for Follicular Lymphoma
|
Program Director: James O. Armitage, MD
|
|
Philip Bierman, MD, provides an interactive, case-based overview of the latest data supporting optimal management strategies for patients with follicular lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Apply prognostic indices and factors to determine personalized treatment approaches for patients with follicular lymphoma
- Integrate standard and emerging treatment regimens demonstrated to improve outcomes for patients with follicular lymphoma who are candidates for therapy
- Propose safe and effective maintenance strategies for patients with follicular lymphoma who have achieved a response to frontline therapy
- Employ individualized management approaches for patients with relapsed or refractory follicular lymphoma including the appropriate use of newer agents and transplantation strategies
|
Slideset: The Evolving Treatment Paradigm for Follicular Lymphoma
 |
|
Download slides focused on standard and investigational treatment strategies for patients with follicular lymphoma.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.21 MB
| Date posted: 7/21/2010
|
Peripheral and Cutaneous T-Cell Lymphomas: Overview and Therapeutic Advances
|
Program Director: James O. Armitage, MD
|
|
In this Interactive Virtual Presentation, Kerry J. Savage, MD, MSc, provides a case-based overview of the latest treatment approaches for patients with peripheral and cutaneous T-cell lymphomas.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Design optimal treatment strategies based on disease subtype–specific prognosis and response for patients with newly diagnosed with peripheral T-cell lymphomas
- Select evidence-based treatment approaches for patients with relapsed/refractory peripheral T-cell lymphomas
- Cite recent data on novel investigational therapies for patients with peripheral T-cell lymphomas
- Plan optimized therapy for patients with cutaneous T-cell lymphomas
|
Slideset: Peripheral and Cutaneous T-Cell Lymphomas: Overview and Therapeutic Advances
 |
|
Download slides focused on standard and investigational treatment strategies for patients with peripheral and cutaneous T-cell lymphoma.
Format: Microsoft PowerPoint (.ppt) |
File size: 25.93 MB
| Date posted: 9/1/2010
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|